Activation of Akt Predicts Poor Outcome in Neuroblastoma

Daniela Opel,¹ Christopher Poremba,² Thorsten Simon,³ Klaus-Michael Debatin,¹ and Simone Fulda¹

¹University Children’s Hospital, Ulm, Germany; ²Institute of Pathology, Heinrich-Heine-University, Düsseldorf, Germany; and ³Children’s Hospital, Paediatric Oncology, University of Cologne, Cologne, Germany

Abstract

Whereas aberrant activation of the phosphatidylinositol 3’-kinase (PI3K)/Akt pathway, a key survival cascade, has previously been linked to poor prognosis in several human malignancies, its prognostic effect in neuroblastoma has not yet been explored. We therefore investigated the phosphorylation status of Akt, S6 ribosomal protein as target of mammalian target of rapamycin, and extracellular signal–regulated kinase (ERK) in 116 primary neuroblastoma samples by tissue microarray and its correlation with established prognostic markers and survival outcome. Here, we provide for the first time evidence that phosphorylation of Akt at serine 473 (S473) and/or threonine 308 (T308), S6 ribosomal protein, and ERK frequently occurs in primary neuroblastoma. Importantly, we identified Akt activation as a novel prognostic indicator of decreased event-free or overall survival in neuroblastoma, whereas phosphorylation of S6 ribosomal protein or ERK had no prognostic effect. In addition, Akt activation correlated with variables of aggressive disease, including MYCN amplification, 1p36 aberrations, advanced disease stage, age at diagnosis, and unfavorable histology. Monitoring Akt at T308 or both phosphorylation sites improved the prognostic significance of Akt activation in neuroblastoma specimens compared with S473 phosphorylation. Parallel experiments in neuroblastoma cell lines revealed that activation of Akt by insulin-like growth factor (IGF)-I significantly inhibited tumor necrosis factor–related apoptosis–inducing ligand– or chemotherapy-induced apoptosis in a PI3K-dependent manner because the PI3K inhibitor LY294002 completely reversed the IGF–I–mediated protection of neuroblastoma cells from apoptosis. By showing that activation of Akt correlates with poor prognosis in primary neuroblastoma in vivo and with apoptosis resistance in vitro, our findings indicate that Akt presents a clinically relevant target in neuroblastoma that warrants further investigation. [Cancer Res 2007;67(2):735–45]

Introduction

Neuroblastoma is the most common extracranial solid tumor in childhood and accounts for 7% to 10% of pediatric malignancies (1). Currently, even intensive, multimodality therapy has resulted in only modest improvement in the cure rate of the more aggressive neuroblastoma (2, 3). Neuroblastoma is a leading cause of morbidity and mortality in children (1). Because a better understanding of the tumor biology of neuroblastoma may lead to biologically based therapies that are more effective and less toxic, there has recently been much interest in identifying molecular pathways that are involved in progression of neuroblastoma (4).

The phosphatidylinositol 3’-kinase (PI3K) pathway, in particular, seems to be one of the most potent prosurvival signaling pathways (5). Deregulated signaling through the PI3K pathway is common in many types of human malignancies, including glioblastoma and breast, prostate, and lung cancers (5, 6). For example, activation of the PI3K/Akt pathway has recently been reported to correlate with increasing tumor grade, decreased apoptosis, and adverse clinical outcome in glioblastoma in vivo (7, 8). Aberrant activation of the PI3K/Akt pathway in cancers can be caused by genetic lesions [e.g., mutations of the tumor suppressor gene phosphatase and tensin homologue (PTEN)] or by tyrosine kinase receptors stimulated by growth factors [e.g., insulin-like growth factor (IGF), epidermal growth factor, or brain-derived neurotrophic factor (BDNF); refs. 5, 9–11]. Critical mediators of PI3K, including Akt and mammalian target of rapamycin (mTOR), are known to enhance cellular survival by stimulating cell proliferation, glucose metabolism, or angiogenesis and by actively suppressing apoptosis (5, 10). Akt is a serine/threonine kinase that is activated by a dual regulatory mechanism that requires both translocation to the plasma membrane and phosphorylation of two key amino acids (5). On growth factor stimulation, PI3K generates phosphatidylinositol 3,4-bisphosphate and phosphatidylinositol-3,4,5-trisphosphate, which bind to the pleckstrin homology domains of Akt and 3’-phosphoinositide-dependent kinase-1 (PDK-1), promoting their translocation to the plasma membrane, where Akt becomes phosphorylated in the catalytic domain at threonine 308 (T308) by PDK-1 (5). In addition, Akt is phosphorylated in the regulatory domain at serine 473 (S473) through mechanisms not completely resolved (5). Phosphorylation of Akt at both T308 and S473 is required for full kinase activity (5). Programmed cell death or apoptosis plays a pivotal role in the regulation of tissue homeostasis, which is maintained by a balance between proliferation and cell death (12–14). Accordingly, a reduction of the physiological rate of apoptosis may contribute to tumor formation and progression (15). In addition, apoptosis has been implicated to mediate therapy-induced cytotoxicity (e.g., following chemotherapy, γ-irradiation, or immunotherapy; ref. 13). Apoptosis pathways may be initiated through the extrinsic (death receptor) or intrinsic (mitochondrial) pathway, resulting in activation of effector caspases (13). Stimulation of death receptors of the tumor necrosis factor (TNF) receptor superfamily such as TNF-related apoptosis-inducing ligand (TRAIL) receptors results in activation of caspase-8, which initiates direct cleavage of downstream effector caspases (16). The mitochondrial pathway is, for example, engaged in response to cytotoxic drug treatment and

Note: Supplementary data for this article are available at Cancer Research Online (http://cancerres.aacrjournals.org/).

Requests for reprints: Simone Fulda, University Children’s Hospital, Eythstrasse 24, D-89075 Ulm, Germany; Phone: 49-731-5002-5980; Fax: 49-731-5002-6765; E-mail: simone.fulda@uniklinik-ulm.de.

©2007 American Association for Cancer Research. doi:10.1158/0008-5472.CAN-06-2201
involves the release of apoptotic factors, such as cytochrome c or second mitochondria-derived activator of caspase (Smac)/direct inhibitor of apoptosis– binding protein with low isolectric point (DIABLO), from mitochondria into the cytosol, triggering caspase-3 activation as a result of formation of the apoptosome complex (17).

Despite growing interest in the PI3K/Akt pathway as cancer drug target in recent years (18, 19), the activation status and the potential clinical prognostic value of components of this pathway have not yet been explored in clinical specimens in neuroblastoma. Therefore, we investigated activation of the PI3K/Akt pathway and its correlation with established prognostic markers and survival outcome in a large cohort of neuroblastoma patients in the present study. Parallel experiments in neuroblastoma cell lines were designed to analyze the effect of elevated PI3K/Akt signaling on apoptosis sensitivity.

Materials and Methods

Tissue Microarray

Patients. A total of 116 patients of the Cooperative German Neuroblastoma Trials NB90, NB95, and NB97 were analyzed by tissue microarray. Briefly, representative tissue blocks were selected as donor blocks for the tissue microarray. Sections were cut from each donor block and stained with H&E. Using these slides, one morphologically representative region was chosen from each of the 116 neuroblastoma samples. One cylindrical core tissue specimen per tumor block (diameter, 2.0 mm) was punched from these regions and precisely arrayed into a new recipient paraffin block using a custom-built precision instrument (Beecher Instruments, Silver Spring, MD). Tumor samples were taken before chemotherapy. Characteristics of patients’ tumors are summarized in Supplementary Table S1.

Immunohistochemistry. Three-micrometer sections were prepared from the tissue microarray and mounted onto silane-coated glass slides. Immunohistochemical analyses were done with rabbit anti–phospho-Akt (S473) monoclonal antibody (1:100; Cell Signaling, Beverly, MA), rabbit anti–phospho-Akt (T308) monoclonal antibody (1:100; Cell Signaling), rabbit anti–phospho-S6 ribosomal protein (S235/236) polyclonal antibody (1:400; Cell Signaling), and rabbit anti–phospho-extracellular signal–regulated kinase (ERK; T202/Y204) monoclonal antibody (E10; 1:400; Cell Signaling). Pretreatment for antigen retrieval was done with pressure cooker (3,3-diaminobenzidine enzymatic development).

Surface Staining

Neuroblastoma cells seeded overnight in 10-cm plates or 75-cm² flasks were treated or not with IGF-I, SH-EP, or SH-SY5Y neuroblastoma cells (5 × 10⁵/cm² and 1 × 10⁶/cm², respectively) were seeded in 24-well plates (Falcon, Heidelberg, Germany), allowed to settle for 24 h, washed once with PBS (Biochrom), pretreated or not with IGF-I or IGF-II for 4 h or with LY294002 for 1 h, and then treated with TRAIL, doxorubicin, or cisplatin in the presence or absence of IGF-I, IGF-II, or LY294002 in serum-free medium. Apoptosis was determined by fluorescence-activated cell sorting (FACS; FACScan, BD Biosciences, Heidelberg, Germany) analysis of DNA fragmentation of propidium iodide–stained nuclei as previously described (21). The percentage of specific apoptosis was calculated as follows: 100 × [experimental apoptosis (%) / [100% – spontaneous apoptosis in medium (%)].

Western Blot Analysis

Neuroblastoma cells seeded overnight in 10-cm plates or 75-cm² flasks were treated or not with IGF-I, IGF-II, or LY294002 in medium containing 0% FCS or 10% FCS for indicated time points. Cells were lysed for 15 min on ice in lysis buffer (30 mmol/L Tris-HCl (pH 7.5), 150 mmol/L NaCl, 1% Triton-X, 10% glycerol, 2 mmol/L DTT, 200 mmol/L phenylmethylsulfonyl fluoride, 1 mmol/L Na₂VO₄, 10 mmol/L okadaic acid, 1 mmol/L β-glycerolphosphate, 1 mmol/L EDTA, 50 mmol/L sodium fluoride, and a mixture of proteinase and proteolobbed onto a Hybond enhanced chemiluminescence nitrocellulose membrane (Amersham Pharmacia Biotech, Freiburg, Germany). Membranes were blocked for 1 h in PBS supplemented with 5% milk powder and 0.1% Tween 20. Membranes were stained overnight with primary antibody, followed by 1-h incubation with horseradish peroxidase–conjugated secondary antibody, and detection was done with enhanced chemiluminescence (Amersham Pharmacia). The following antibodies were used: rabbit anti–phospho-Akt (S473) polyclonal antibody (1:1,000; Cell Signaling), rabbit anti–phospho-Akt (T308) monoclonal antibody (244G; 1:1,000; Cell Signaling), mouse anti-Akt monoclonal antibody (1:500; BD Bioscience), rabbit anti–phospho-S6 ribosomal protein (S235/236) polyclonal antibody (1:1,000; Cell Signaling), rabbit anti–S6 ribosomal protein polyclonal antibody (1:1,000; Cell Signaling), mouse anti–phospho-ERK (T202/Y204) monoclonal antibody (E10; 1:2,000; Cell Signaling), or rabbit anti–ERK polyclonal antibody (1:10,000; Sigma). Horseradish peroxidase–conjugated goat anti-mouse

Cancer Res 2007; 67: (2). January 15, 2007 736 www.aacrjournals.org
IgG or goat anti-rabbit IgG (1:5,000) was obtained from Santa Cruz Biotechnology (Santa Cruz, CA). Mouse anti–β-actin monoclonal antibody (1:5,000; Sigma) was used as loading control.

Results

Activation of the PI3K/Akt pathway in primary neuroblastoma samples. Whereas the PI3K/Akt pathway has elicited intense interest as drug target in several types of cancer (6–8), its activation status has not yet been explored in neuroblastoma in vivo. Therefore, we analyzed phosphorylation of Akt, a target of PI3K, and S6 ribosomal protein, a target of mTOR, as read-outs for activation of upstream and downstream components of the pathway by immunohistochemistry using a human tissue microarray composed of 116 primary neuroblastoma specimens. Because full activation of Akt requires phosphorylation of two key amino acids in the regulatory (S473) and catalytic domains (T308; ref. 5), we monitored phosphorylation of both sites to allow a thorough analysis of Akt activation. We found that Akt was highly phosphorylated at S473 in 61.2% (71 of 116) and at T308 in 62.9% (73 of 116) of primary neuroblastoma (Fig. 1A). Of 116 tumors, 66 (56.9%) were positive for both phosphospecific Akt antibodies (Fig. 1A and B). Five of 116 (4.3%) of neuroblastoma specimens were positive for S473 phosphorylation but not T308 phosphorylation, whereas 7 of 116 (6%) were positive for T308 phosphorylation but not S473 phosphorylation (Fig. 1B). Thirty-eight of 116 (32.8%) tumors showed low phosphorylation of both sites (Fig. 1B). Strong phosphorylation of S6 ribosomal protein, a target of mTOR, occurred in 55.2% (64 of 116) of neuroblastoma samples.

Figure 1. Activation of the PI3K/Akt pathway in primary neuroblastoma samples. Phosphorylation of Akt, S6 ribosomal protein, and ERK was analyzed in primary neuroblastoma samples by immunohistochemistry on a tissue microarray chip containing 116 neuroblastoma samples. A, percentage of tumor samples showing high (+) or low (−) phosphorylation of Akt at S473 (AktS473), at T308 (AktT308), at both S473 and T308 (AktS473/T308), S6 ribosomal protein, and ERK. B, number and percentage of neuroblastoma samples with low (−) or high (+) phosphorylation of Akt at S473 and/or T308. C, representative immunohistochemical stainings of phospho-AktS473 (a and b), phospho-AktT308 (c and d), phospho-S6 ribosomal protein (e and f), and phospho-ERK (g and h). Magnification, ×20 (a, c, e, and g), ×200 (b, d, f, and h).
Table 1. Correlation of the phosphorylation status of Akt, S6 ribosomal protein, or ERK and variables of aggressive disease in primary neuroblastoma

<table>
<thead>
<tr>
<th>MYCN</th>
<th>Low p-AktS473</th>
<th>High p-AktS473</th>
<th>Low p-AktT308</th>
<th>High p-AktT308</th>
</tr>
</thead>
<tbody>
<tr>
<td>(A) Phosphorylation status of Akt, S6, or ERK and MYCN amplification</td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Nonamplified</td>
<td>40/41 (97.6%)</td>
<td>56/69 (81.2%)</td>
<td>40/40 (100%)</td>
<td>56/70 (80.0%)</td>
</tr>
<tr>
<td>Amplified</td>
<td>1/41 (2.4%)</td>
<td>13/69 (18.8%)</td>
<td>0/40 (0%)</td>
<td>14/70 (20.0%)</td>
</tr>
<tr>
<td>Fisher's test</td>
<td></td>
<td>P = 0.016</td>
<td></td>
<td>P = 0.002</td>
</tr>
<tr>
<td>(B) Phosphorylation status of Akt, S6, or ERK and 1p36 aberrations</td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>No aberrations</td>
<td>19/19 (100%)</td>
<td>18/25 (72%)</td>
<td>20/20 (100%)</td>
<td>17/24 (70.8%)</td>
</tr>
<tr>
<td>Aberrations</td>
<td>0/19 (0%)</td>
<td>7/25 (28%)</td>
<td>0/20 (0%)</td>
<td>7/24 (29.2%)</td>
</tr>
<tr>
<td>Fisher's test</td>
<td></td>
<td>P = 0.014</td>
<td></td>
<td>P = 0.011</td>
</tr>
<tr>
<td>(C) Phosphorylation status of Akt, S6, or ERK and disease stage</td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Stage I–III</td>
<td>34/45 (75.6%)</td>
<td>42/71 (59.2%)</td>
<td>35/43 (81.4%)</td>
<td>41/73 (56.2%)</td>
</tr>
<tr>
<td>Stage IV</td>
<td>9/45 (20.0%)</td>
<td>25/71 (35.2%)</td>
<td>6/43 (14.0%)</td>
<td>28/73 (38.4%)</td>
</tr>
<tr>
<td>Stage IVS</td>
<td>2/45 (4.4%)</td>
<td>4/71 (5.6%)</td>
<td>2/43 (4.7%)</td>
<td>4/73 (5.5%)</td>
</tr>
<tr>
<td>Fisher's test</td>
<td></td>
<td>P = 0.184</td>
<td></td>
<td>P = 0.017</td>
</tr>
<tr>
<td>(D) Phosphorylation status of Akt, S6, or ERK and age 12 mo at diagnosis</td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Age &lt;12 mo</td>
<td>14/45 (31.1%)</td>
<td>23/71 (32.4%)</td>
<td>14/43 (32.6%)</td>
<td>23/73 (31.5%)</td>
</tr>
<tr>
<td>Age &gt;12 mo</td>
<td>31/45 (68.9%)</td>
<td>48/71 (67.6%)</td>
<td>29/43 (67.4%)</td>
<td>50/73 (68.5%)</td>
</tr>
<tr>
<td>Fisher's test</td>
<td></td>
<td>P = 1.000</td>
<td></td>
<td>P = 1.000</td>
</tr>
<tr>
<td>(E) Phosphorylation status of Akt, S6, or ERK and age 18 mo at diagnosis</td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Age &lt;18 mo</td>
<td>30/45 (66.6%)</td>
<td>41/71 (57.7%)</td>
<td>31/43 (72.1%)</td>
<td>40/73 (54.8%)</td>
</tr>
<tr>
<td>Age &gt;18 mo</td>
<td>15/45 (33.3%)</td>
<td>30/71 (42.3%)</td>
<td>12/43 (27.9%)</td>
<td>33/73 (45.2%)</td>
</tr>
<tr>
<td>Fisher's test</td>
<td></td>
<td>P = 0.43</td>
<td></td>
<td>P = 0.077</td>
</tr>
<tr>
<td>(F) Phosphorylation status of Akt, S6, or ERK and age 24 mo at diagnosis</td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Age &lt;24 mo</td>
<td>33/45 (73.3%)</td>
<td>45/71 (63.4%)</td>
<td>34/43 (79.1%)</td>
<td>44/73 (60.3%)</td>
</tr>
<tr>
<td>Age &gt;24 mo</td>
<td>12/45 (26.7%)</td>
<td>26/71 (36.6%)</td>
<td>9/43 (20.9%)</td>
<td>29/73 (39.7%)</td>
</tr>
<tr>
<td>Fisher's test</td>
<td></td>
<td>P = 0.313</td>
<td></td>
<td>P = 0.042</td>
</tr>
<tr>
<td>(G) Phosphorylation status of Akt, S6, or ERK and Shimada classification</td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Favorable</td>
<td>34/42 (81.0%)</td>
<td>41/66 (62.1%)</td>
<td>35/40 (87.5%)</td>
<td>40/68 (58.8%)</td>
</tr>
<tr>
<td>Unfavorable</td>
<td>8/42 (19.0%)</td>
<td>25/66 (37.9%)</td>
<td>5/40 (12.5%)</td>
<td>28/68 (41.2%)</td>
</tr>
<tr>
<td>Fisher's test</td>
<td></td>
<td>P = 0.053</td>
<td></td>
<td>P = 0.002</td>
</tr>
</tbody>
</table>

NOTE: Phosphorylation of Akt at S473 (AktS473) or at T308 (AktT308), S6 ribosomal protein, and ERK was analyzed by immunohistochemistry on a tissue microarray and correlated with MYCN amplification (A), 1p36 aberrations (B), disease stage (C), age at diagnosis (D–F), or Shimada classification (F) using χ² test or Fisher's exact test (Fisher's) as indicated. Statistically significant correlations are indicated in bold; AktS/T, Akt phosphorylation at S473 and T308; mo, months.

(Fig. 1A). Because interactions between the PI3K/Akt and the Raf/mitogen-activated protein kinase kinase (MEK)/ERK pathways have been described (22–24), we also assessed phosphorylation of ERK, a direct target of MEK. High phosphorylation of ERK was detected in 48.3% (56 of 116) of primary neuroblastoma specimens (Fig. 1A). Representative immunohistochemical stainings of phospho-Akt (S473 and T308), phospho-S6 ribosomal protein, and phospho-ERK are shown in Fig. 1C.

We also investigated whether there is a correlation among the phosphorylation status of Akt, S6 ribosomal protein, and ERK. We found a correlation of phosphorylation of Akt at S473, T308, or both S473 and T308 and S6 ribosomal protein (P = 0.004, P = 0.004, and P = 0.001, respectively; χ² test), phosphorylation of Akt at S473 and T308 (P = <0.001, χ² test), phosphorylation of S6 ribosomal protein and ERK (P = <0.001, χ² test), as well as phosphorylation of Akt at S473 or both S473 and T308 and ERK (P = 0.036 and P = 0.015, respectively; χ² test), whereas there was no correlation of phosphorylation of Akt at T308 and ERK (P = 0.18, χ² test). These results may reflect that Akt and S6 ribosomal protein are upstream and downstream components of the PI3K/Akt/mTOR pathway and that cross-talks between ERK and the PI3K/Akt/mTOR pathway may exist, which can both be activated by ligation of growth factor receptors (9). Together, this set of experiments shows that phosphorylation of Akt at S473 and/or T308 as well as phosphorylation of S6 ribosomal protein and ERK occurs in a large proportion of neuroblastoma specimens. This indicates that the PI3K/Akt and Raf/MEK/ERK pathways are frequently activated in neuroblastoma in vivo.

Activation of the PI3K/Akt pathway and advanced disease. We next asked whether or not activation of the PI3K/Akt pathway was associated with variables of advanced disease in neuroblastoma. To address this question, we correlated phosphorylation of Akt, S6 ribosomal protein, or ERK with various established variables used for prognostic stratification of neuroblastoma, including MYCN amplification, 1p36 aberrations, stage of disease, age at diagnosis, and tumor histology (1). Interestingly, we found that high phosphorylation of Akt at S473, T308, or both phosphorylation sites significantly correlated with MYCN amplification or 1p36 aberrations (Table 1A and B). The level of significance increased for correlation of Akt phosphorylation and MYCN amplification, when phosphorylation at T308 or at both sites was assessed compared with phosphorylation at S473 (Table 1A). In addition, there was a
stronger correlation between phosphorylation of both Akt sites and 1p36 aberrations compared with either phosphorylation site alone (Table 1B). Moreover, Akt phosphorylation at T308 or at both sites, but not at S473, correlated with stage IV disease, age >24 months at diagnosis, and unfavorable histology according to Shimada classification (Table 1C, F, and G). These findings indicate that monitoring Akt at T308 or both phosphorylation sites improves the assessment of Akt activation. In contrast, no significant association was observed between high phosphorylation of S6 ribosomal protein or ERK and any of the variables tested (Table 1).

Thus, Akt activation, but not phosphorylation of S6 ribosomal protein as read-out of mTOR activity or ERK, correlates with event-free and overall survival of neuroblastoma patients. (Fig. 2B and C; Table 2). These findings show that high phosphorylation of Akt, but not of S6 ribosomal protein as read-out of mTOR activity or ERK, predicts event-free and overall survival of neuroblastoma patients.

### Activation of the PI3K/Akt pathway in neuroblastoma cell lines

We then went on to evaluate the prognostic value of the PI3K/Akt pathway in neuroblastoma. All patients were treated according to the protocols of the Cooperative German Neuroblastoma Trials (NB90, NB95, and NB97). The cumulative event-free survival curves of neuroblastoma patients with high or low phosphorylation of Akt, S6 ribosomal protein, or ERK in tumor samples are shown in Fig. 2, and 3-year event-free and overall survival of patients are summarized in Table 2. Importantly, we found that high phosphorylation of Akt at S473, T308, or both sites significantly correlated with reduced event-free and overall survival in Kaplan-Meier analysis for the group of 116 neuroblastoma patients (Fig. 2A; Table 2). Monitoring Akt at T308 or both phosphorylation sites improved the predictive prognostic value of Akt activation compared with Akt phosphorylation at S473. In contrast, high phosphorylation of S6 ribosomal protein or ERK was not associated with event-free or overall survival of neuroblastoma patients (Fig. 2B and C; Table 2). These findings show that high phosphorylation of Akt, but not of S6 ribosomal protein as read-out of mTOR activity or ERK, predicts event-free and overall survival of neuroblastoma patients.

### Table 1. Correlation of the phosphorylation status of Akt, S6 ribosomal protein, or ERK and variables of aggressive disease in primary neuroblastoma (Cont’d)

<table>
<thead>
<tr>
<th>Low p-AktS/T</th>
<th>High p-AktS/T</th>
<th>Low p-S6</th>
<th>High p-S6</th>
<th>Low p-ERK</th>
<th>High p-ERK</th>
</tr>
</thead>
<tbody>
<tr>
<td>45/45 (100%)</td>
<td>51/65 (78.5%)</td>
<td>42/49 (85.7%)</td>
<td>54/61 (8.5%)</td>
<td>50/57 (87.7%)</td>
<td>46/53 (86.8%)</td>
</tr>
<tr>
<td>0/45 (0%)</td>
<td>14/65 (21.5%)</td>
<td>7/49 (14.3%)</td>
<td>7/61 (11.5%)</td>
<td>7/57 (12.3%)</td>
<td>7/53 (13.2%)</td>
</tr>
<tr>
<td><strong>P = 0.001</strong></td>
<td></td>
<td></td>
<td><strong>P = 0.776</strong></td>
<td></td>
<td><strong>P = 1,000</strong></td>
</tr>
<tr>
<td>22/22 (100%)</td>
<td>15/22 (68.2%)</td>
<td>15/18 (83.3%)</td>
<td>22/26 (84.6%)</td>
<td>22/26 (84.6%)</td>
<td>15/18 (83.3%)</td>
</tr>
<tr>
<td><strong>P = 0.011</strong></td>
<td></td>
<td></td>
<td><strong>P = 1,000</strong></td>
<td></td>
<td><strong>P = 1,000</strong></td>
</tr>
<tr>
<td>39/50 (78.0%)</td>
<td>37/66 (56.1%)</td>
<td>37/52 (71.2%)</td>
<td>39/64 (60.9%)</td>
<td>43/60 (71.6%)</td>
<td>33/56 (58.9%)</td>
</tr>
<tr>
<td>9/50 (18.0%)</td>
<td>25/66 (37.9%)</td>
<td>14/52 (26.9%)</td>
<td>20/64 (31.3%)</td>
<td>14/60 (23.3%)</td>
<td>20/56 (35.7%)</td>
</tr>
<tr>
<td>4/73 (5.5%)</td>
<td>4/66 (6.1%)</td>
<td>1/52 (1.9%)</td>
<td>5/64 (7.8%)</td>
<td>3/60 (5%)</td>
<td>3/56 (5.4%)</td>
</tr>
<tr>
<td><strong>P = 0.046</strong></td>
<td></td>
<td></td>
<td><strong>P = 0.277</strong></td>
<td></td>
<td><strong>P = 0.326</strong></td>
</tr>
<tr>
<td>16/50 (32.0%)</td>
<td>21/66 (31.8%)</td>
<td>21/52 (40.4%)</td>
<td>16/64 (25.0%)</td>
<td>21/60 (35.0%)</td>
<td>16/56 (28.6%)</td>
</tr>
<tr>
<td>34/50 (68.0%)</td>
<td>45/66 (68.2%)</td>
<td>31/52 (59.6%)</td>
<td>48/64 (75.0%)</td>
<td>39/60 (65.0%)</td>
<td>40/56 (71.4%)</td>
</tr>
<tr>
<td><strong>P = 1,000</strong></td>
<td></td>
<td></td>
<td><strong>P = 0.109</strong></td>
<td></td>
<td><strong>P = 0.551</strong></td>
</tr>
<tr>
<td>35/50 (70.0%)</td>
<td>36/66 (54.5%)</td>
<td>35/52 (67.3%)</td>
<td>36/64 (56.3%)</td>
<td>37/60 (61.6%)</td>
<td>34/56 (60.7%)</td>
</tr>
<tr>
<td>15/50 (30.0%)</td>
<td>30/66 (46.5%)</td>
<td>17/52 (32.7%)</td>
<td>28/64 (43.7%)</td>
<td>23/60 (38.4%)</td>
<td>22/56 (39.3%)</td>
</tr>
<tr>
<td><strong>P = 0.057</strong></td>
<td></td>
<td></td>
<td><strong>P = 0.254</strong></td>
<td></td>
<td><strong>P = 1,000</strong></td>
</tr>
<tr>
<td>38/50 (76.0%)</td>
<td>40/66 (60.6%)</td>
<td>36/52 (69.2%)</td>
<td>42/64 (65.6%)</td>
<td>40/60 (66.7%)</td>
<td>38/56 (67.9%)</td>
</tr>
<tr>
<td>12/50 (24.0%)</td>
<td>26/66 (39.4%)</td>
<td>16/52 (30.8%)</td>
<td>22/64 (34.4%)</td>
<td>20/60 (33.3%)</td>
<td>18/56 (32.1%)</td>
</tr>
<tr>
<td><strong>P = 0.048</strong></td>
<td></td>
<td></td>
<td><strong>P = 0.696</strong></td>
<td></td>
<td><strong>P = 1,000</strong></td>
</tr>
<tr>
<td>12/50 (24.0%)</td>
<td>36/61 (59.0%)</td>
<td>38/50 (76.0%)</td>
<td>37/58 (63.8%)</td>
<td>40/57 (70.2%)</td>
<td>35/51 (68.6%)</td>
</tr>
<tr>
<td>8/47 (17.0%)</td>
<td>25/61 (41.0%)</td>
<td>12/50 (24.0%)</td>
<td>21/58 (36.2%)</td>
<td>17/57 (29.8%)</td>
<td>16/51 (31.4%)</td>
</tr>
<tr>
<td><strong>P = 0.006</strong></td>
<td></td>
<td></td>
<td><strong>P = 0.211</strong></td>
<td></td>
<td><strong>P = 1,000</strong></td>
</tr>
</tbody>
</table>
in SK-N-BE, Kelly, and IMR32 neuroblastoma cells even in the absence of serum (Fig. 3). U87MG glioblastoma cells were used as a positive control for constitutive phosphorylation of Akt, S6 ribosomal protein, and ERK even under serum deprivation (Fig. 3).

Growth factors (e.g., IGF-I) are known to stimulate Akt (10). Because the IGF system has been implicated to play an important role in neuroblastoma biology (11), we next used IGF-I to activate Akt. Stimulation of neuroblastoma cells with IGF-I resulted in strong phosphorylation of AktS473 and S6 ribosomal protein (Fig. 3). By comparison, phosphorylation of ERK was enhanced by IGF-I in some cell lines (i.e., SK-N-BE, SK-N-AS, Kelly, and IMR32 cells; Fig. 3). Monitoring Akt phosphorylation at T308 yielded similar results compared with phosphorylation of Akt at S473 in neuroblastoma cell lines (Supplementary Fig. S1). We therefore assessed Akt phosphorylation at S473 to determine Akt activation in SH-EP and SH-SY5Y neuroblastoma cells in subsequent

![Figure 2](image.png)

**Figure 2.** Activation of the PI3K/Akt pathway and survival. The Kaplan-Meier curves show the probability of event-free survival (EFS) of neuroblastoma patients in terms of high or low phosphorylation of Akt at S473, Akt at T308, or Akt at both S473 and T308 (A), S6 ribosomal protein (B), and ERK (C) as determined by tissue microarray. The survival curves were analyzed by the log-rank test and the levels of significance are indicated.
activation of Akt on stimulation with IGF-I.

**Activation of Akt rescues neuroblastoma cells from cytotoxic drug- or TRAIL-induced apoptosis.** In light of our findings that activation of Akt correlates with poor prognosis in neuroblastoma, we wished to explore in more detail the role of the PI3K/Akt survival cascade in regulating apoptosis in neuroblastoma cells. To address this issue, we used IGF-I to stimulate Akt activation in prototype S-type (SH-EP) and N-type (SH-SY5Y) neuroblastoma cell lines. S-type (substrate adherent) and N-type (neuroblastic) cell lines are considered to correspond to distinct cell types present in human neuroblastoma tumors (25).

As shown in Fig. 4A, both SH-EP and SH-SY5Y neuroblastoma cells express IGF receptor on their cell surface. Stimulation with IGF-I resulted in rapid and prolonged phosphorylation of Akt (Fig. 4B). In addition, treatment with IGF-I rapidly triggered phosphorylation of S6 ribosomal protein (Fig. 4B). Compared with Akt, phosphorylation of S6 ribosomal protein was transient and declined after 24 h, and then became undetectable at 48 h (Fig. 4B).

Because childhood tumors such as neuroblastoma have been reported to preferentially express IGF-II (26), we also compared activation of Akt by IGF-I and IGF-II. As shown in Fig. 4B, IGF-I and IGF-II similarly stimulated phosphorylation of Akt in SH-EP neuroblastoma cells. Because we observed no differences between IGF-I and IGF-II in their ability to activate Akt, we used IGF-I for further experiments.

Next, we investigated whether or not activation of Akt interferes with the ability of neuroblastoma cells to undergo apoptosis. To this end, SH-EP and SH-SY5Y neuroblastoma cells were left untreated or were pretreated with IGF-I for 4 h to stimulate Akt before apoptosis was induced in the presence or absence of IGF-I. Importantly, activation of Akt by pretreatment with IGF-I significantly reduced doxorubicin-induced apoptosis in both SH-EP and SH-SY5Y neuroblastoma cells in a dose- and time-dependent manner (Fig. 4C). Similarly, activation of Akt by pretreatment with IGF-I resulted in a significant decrease of cisplatin-induced apoptosis in SH-EP and SH-SY5Y neuroblastoma cells (Fig. 4C).

To examine whether or not apoptosis resistance mediated by Akt was restricted to cytotoxic drugs, which predominately activate

![Figure 3](image-url)

**Figure 3.** Activation of the PI3K/Akt pathway in neuroblastoma cell lines. SK-N-SH, SK-N-BE, SK-N-AS, SH-EP, Kelly, SH-SY5Y, and IMR32 neuroblastoma cells were cultured for 24 h in medium containing 0% FCS (1), or were cultured for 24 h in medium containing 10% FCS (3). U87MG glioblastoma cells cultured for 24 h in medium containing 0% FCS (1) or 10% FCS (3) were used as a positive control for phosphorylation of Akt, S6 ribosomal protein, and ERK. Protein levels of phospho-Akt, Akt, phospho-S6 ribosomal protein, S6 ribosomal protein, phospho-ERK, ERK, and β-actin were assessed by Western blot analysis.
Figure 4. Activation of Akt rescues neuroblastoma cells from cytotoxic drug– or TRAIL-induced apoptosis. A, IGF-I receptor expression in neuroblastoma cell lines. Surface expression of IGF-I receptor on SH-EP and SH-SYSY neuroblastoma cells was determined by FACS analysis using IGF-I receptor antibody (black) or isotype control (gray). B, effect of IGF-I and IGF-II on phosphorylation of Akt, S6 ribosomal protein, and ERK. SH-EP or SH-SYSY neuroblastoma cells were cultured medium containing 0% or 10% FCS or were stimulated with 200 ng/mL IGF-I or IGF-II in medium containing 0% FCS for indicated time points. Protein levels of phospho-AktS473, Akt, phospho-S6 ribosomal protein, S6 ribosomal protein, phospho-ERK, ERK, and β-actin were assessed by Western blot. C, effect of IGF-I on cytotoxic drug– or TRAIL-induced apoptosis. SH-EP or SH-SYSY neuroblastoma cells were pretreated or not with 200 ng/mL IGF-I for 4 h and then treated with doxorubicin, cisplatin, or TRAIL in the absence (○) or presence (●) of 200 ng/mL IGF-I for indicated times and concentrations. Apoptosis was measured by FACS analysis of DNA fragmentation of propidium iodide–stained nuclei; percentage of specific apoptosis is shown. Columns, mean of three independent experiments done in duplicates or triplicates; bars, SE. Apoptosis in the presence of IGF-I alone was <5%. *, P < 0.05; **, P < 0.001, treatment with IGF-I versus treatment without IGF-I (Student’s t test).
the intrinsic pathway of apoptosis, we then extended our studies to
the extrinsic pathway using the death receptor ligand TRAIL. In
addition, activation of Akt by IGF-I significantly reduced TRAIL-
induced apoptosis in SH-EP cells (Fig. 4C). TRAIL could not
be assessed in SH-SY5Y cells because they lack expression of
caspase-8, which is an essential component of the apoptotic
signal transduction pathway triggered by TRAIL (27). Together,
these findings show that activation of Akt by IGF-I reduces
anticancer drug– or TRAIL-induced apoptosis in both S- and
N-type neuroblastoma cells.

Inhibition of PI3K/Akt abolishes IGF-I–mediated protection
against doxorubicin- or TRAIL-induced apoptosis. IGF-I has
been reported to mediate survival via the PI3K/Akt and/or Raf/
MEK/ERK pathway (28). Therefore, to further elucidate the specific
contribution of PI3K/Akt to IGF-I–mediated apoptosis resistance,
we used LY294002, a competitive and reversible inhibitor of the
ATP-binding site of PI3K (29). To analyze whether or not inhibition
of PI3K by LY294002 was effective in neuroblastoma cells, we
determined phosphorylation of Akt, a downstream target of PI3K,
by Western blot analysis. As shown in Fig. 5A and B, LY294002
strongly inhibited phosphorylation of Akt in response to stimula-
tion with IGF-I in a concentration-dependent manner. Next, we
investigated the ability of IGF-I to protect neuroblastoma cells
against doxorubicin- or TRAIL-induced apoptosis in the presence
or absence of the PI3K inhibitor LY294002. Importantly, inhibition
of PI3K by LY294002 completely reversed the IGF-I–mediated
protection against doxorubicin- or TRAIL-induced apoptosis (Fig. 5C
and D). This shows that IGF-I confers resistance towards
doxorubicin- or TRAIL-induced apoptosis in a PI3K-dependent
manner in neuroblastoma cells.

Discussion
Despite intensive, multimodality therapy, the cure rate of
advanced neuroblastoma has only modestly improved in recent
years (1). Therefore, a better understanding of the pathways
responsible for neuroblastoma progression and treatment
resistance may lead to the development of more effective, less
toxic therapies (4). The PI3K/Akt pathway is a key mediator of
cell survival signals, and human malignancies with high active
Akt levels have been reported to be resistant to various treat-
ments (5, 18). Whereas deregulated signaling via the PI3K/Akt
pathway has been associated with poor prognosis in several
human cancers (5), the question whether or not the activation
status of key components of this survival cascade bears prognostic
effect on outcome in neuroblastoma has not previously been
addressed.

Here, we provide for the first time evidence that phosphorylation
of Akt at S473 and/or T308, S6 ribosomal protein, and ERK is a
frequent event in neuroblastoma. Moreover, we identified Akt
activation as a novel prognostic indicator of reduced event-free or
overall survival in neuroblastoma. In addition, Akt activation
 correlated with established variables of aggressive disease,
including MYCN amplification, Ip36 aberrations, advanced disease
stage, age at diagnosis, and unfavorable histology. Monitoring Akt
at T308 or both phosphorylation sites compared with S473
phosphorylation improved the assessment of Akt activation in
neuroblastoma samples. In contrast to Akt, phosphorylation of S6
ribosomal protein or ERK did not correlate with survival or
variables of advanced disease in neuroblastoma. The findings in
primary neuroblastoma samples were corroborated by parallel
experiments in neuroblastoma cell lines showing that activation
of Akt by IGF-I protected neuroblastoma cells from TRAIL-
or chemotherapy-induced apoptosis in a PI3K-dependent manner.
Together, these data suggest that Akt presents a clinically
relevant target to enhance the efficacy of cytotoxic therapies in
neuroblastoma.

Aberrant activation of Akt has previously been linked to poor
prognosis in other human malignancies (e.g., glioblastoma and
breast carcinoma; refs. 6, 7). Our study is the first to report a
correlation between the activation status of Akt and reduced
survival in neuroblastoma. Thus, it extends the clinical relevance
of Akt to the most common extracranial solid tumor of childhood.
Assessment of Akt activation by monitoring phosphorylation at
T308 or at both T308 and S473 improved the prognostic
significance of Akt activation in neuroblastoma specimens
compared with determining only S473 phosphorylation. Similarly,
evaluation of both Akt phosphorylation sites has recently been
reported to improve the assessment of Akt activation in non-
small-cell lung cancer (30). This may reflect that phosphorylation
of both sites is required for full activation of Akt (5). Accordingly,
S473 phosphorylation does not necessarily correlate with Akt
activity (e.g., in PDK-1-deficient cells that lack T308 phosphoryla-
tion on IGF-I stimulation; ref. 31). Thus, evaluation of both T308
and S473 phosphorylation may be a better surrogate for Akt
activity in clinical specimens. Our finding that Akt activation
 correlated with several variables of aggressive disease in neuroblas-
toma, including MYCN amplification, Ip36 aberrations, advanced
disease stage, age at diagnosis, and unfavorable histology, may
reflect its association with poor prognosis. Alternatively, correla-
tion of phosphorylated Akt with MYCN amplification and Ip36
aberrations may point to a novel link between Akt and genetic
aberrations in neuroblastoma because activation of Akt has
recently been reported to contribute to genomic instability of
tumor cells (32, 33). However, whether or not such a link between
Akt and genomic instability exists in neuroblastoma is subject
to future investigations. Because only phosphorylation of Akt,
but not of ERK or S6 ribosomal protein, was prognostically
significant, although there was a correlation among the three
phospho-proteins analyzed, these findings suggest that these
proteins may primarily control distinct pathways with differential
prognostic effects (e.g., metabolism, differentiation, cell death,
and survival).

The PI3K/Akt pathway can be up-regulated in human cancers
through several mechanisms. Perhaps the most commonly known
mechanisms comprise mutations or deletions of key components
of the signaling cascade (e.g., PTEN or PIK3CA) or through
amplification or overexpression of critical growth factor receptors
(9, 10, 34). The cause of Akt activation in neuroblastoma may
involve deregulated growth factor signaling (e.g., triggered by the
IGF system in a paracrine or autocrine manner; ref. 11). In support
of this notion, we found strong phosphorylation of Akt in
neuroblastoma cells stimulated with IGF-I or IGF-II in line with
other reports (35, 36). As neuroblastoma is a tumor of the neural
crest, neurotrophins and their receptors (e.g., nerve growth factor/
TrkA and BDNF/TrkB) are also likely involved in regulating Akt
activation in vivo (1). BDNF/TrkB stimulation has been reported
to activate the PI3K/Akt pathway in neuroblastoma cells (37–39).
It will be subject to future studies to explore activators of Akt
in neuroblastoma in vivo (e.g., by correlating Akt phosphorylation
with expression of TrkA, TrkB, or IGF receptors and their corres-
ponding ligands). Deletions of the tumor suppressor gene PTEN, an
antagonists of PI3K signaling, are rare in neuroblastoma (40), whereas PTEN mutations are a frequent cause of aberrant activation of PI3K/Akt in glioblastoma (41). Collectively, these findings support a model where activation of Akt in neuroblastoma may predominantly be caused by elevated signaling through growth factor receptors, promoting growth and conferring resistance to cell death.

Our findings that activation of Akt by IGF-I protected neuroblastoma cells against TRAIL- or cytotoxic drug–induced apoptosis are in line with mounting evidence that activation of this survival cascade can rescue neuroblastoma cells from cell death (e.g., in response to anticancer agents). To this end, aberrant stimulation of the BDNF/TrkB pathway was reported to enhance resistance of neuroblastoma cells to chemotherapy in a PI3K-dependent manner (37, 39). Using pharmacologic and genetic tools, Akt was recently identified as a key component of the BDNF/TrkB–mediated survival signaling and chemoresistance in neuroblastoma cells (38). Previously, IGF-I has been reported to rescue neuroblastoma cells from hyperosmotic stress–, peroxynitrite–, hypoxia–, doxorubicin–, or TNFα–induced apoptosis (36, 42–45). Our study extends these findings by showing that IGF-I also protects neuroblastoma cells from apoptosis induced by the death-inducing ligand TRAIL. Together, these data indicate that activation of Akt by IGF-I confers resistance to neuroblastoma cells against a variety of cytotoxic stimuli. Because there is accumulating evidence that TRAIL may play an important role as effector molecule of the innate immune response in tumor surveillance (46), protection from TRAIL-induced apoptosis by activation of Akt may promote progression of neuroblastoma. In addition, recombinant soluble TRAIL and agonistic TRAIL receptor antibodies are currently evaluated in early clinical trials for the treatment of cancer. Thus, strategies to enhance the efficacy of TRAIL-based therapies (e.g., small-molecule PI3K inhibitors) are particularly interesting for molecular targeted cancer therapy in neuroblastoma.

By showing that high phosphorylation of Akt in vivo correlates with reduced survival of neuroblastoma patients and that activation of Akt protects neuroblastoma cells against TRAIL- or chemotherapy-induced apoptosis, our results indicate that Akt plays an important role in promoting survival in neuroblastoma. These findings have clinical implications for the development of experimental approaches in neuroblastoma therapy because resistance to undergo programmed cell death is a major cause of nonresponsiveness of cancers, such as neuroblastoma, leading to treatment failure. Thus, Akt represents a clinically relevant target (e.g., using small-molecule inhibitors) to enhance the efficacy of anticancer therapy and to attain therapeutic gain in the treatment of neuroblastoma.

Acknowledgments

Received 6/15/2006; revised 10/9/2006; accepted 11/9/2006.

Grant support: Deutsche Forschungsgemeinschaft and the Deutsche Krebshilfe (S. Fulda and K-M. Debatin).

The costs of publication of this article were defrayed in part by the payment of page charges. This article must therefore be hereby marked advertisement in accordance with 18 U.S.C. Section 1734 solely to indicate this fact.

We thank S. Piater and K. Scharrmann for expert technical assistance.
Role of Akt in Neuroblastoma

References